- What the market looks like?
- What are the market growth drivers?
The high incidence of autoimmune diseases, increasing awareness about autoimmune diseases, and the growth in research on autoimmune diseases, are driving the growth of the global market. Moreover, the use of biosensors for autoimmune disease diagnosis is expected to offer significant growth opportunities to the autoimmune disease diagnosis market players in the coming years.
According to the recent report "Autoimmune Disease Diagnosis Market by Product (Consumables, Assay Kits, Instruments), Test Type (Inflammatory Markers, Routine Laboratory Tests), Disease (RA, SLE, Thyroiditis, Scleroderma), End User (Hospitals, Clinical Labs) - Global Forecast to 2025" The global autoimmune disease diagnosis industry size is projected to reach USD 6.3 billion by 2025 from USD 4.1 billion in 2020, growing at a CAGR of 8.9% from 2020 to 2025
Download PDF Brochure:
Clinical laboratories accounted for the largest share of the autoimmune disease diagnosis market, by the end-user, in 2019
The end user segment of this market is categorized into clinical laboratories, hospitals, and other end-users. The clinical laboratory segment is expected to grow at the highest growth rate during the forecast period. Highly advanced infrastructure to carry out various test procedures is the major driving factor of this segment.
Europe was the largest regional market for autoimmune disease diagnosis market in 2019
By region, the autoimmune disease diagnosis industry is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2019, Europe accounted for the largest market share, followed by North America. The increased R&D expenditure made by European countries, the presence of players, along with research activities by organizations and associations in the region are the major factors supporting the growth of the autoimmune disease diagnosis industry.
Request Sample Report:
The prominent players operating in the global autoimmune disease diagnosis market include Thermo Fisher Scientific (US), Siemens (Germany), Abbott (US), Danaher (US), Bio-Rad Laboratories (US), Grifols (Spain), Trinity Biotech (Ireland), Werfen (Spain), HYCOR Biomedical (US), EUROIMMUN AG (Germany), Oncimmune (UK), HTG Molecular Diagnostics (US), Seramun Diagnostica GmbH (Germany), Exagen Inc. (US), Cambridge Life Sciences Limited (UK), A. Menarini Diagnostics s.r.l (OTCPK:ITALY), ORGENTEC Diagnostika (Germany), KRONUS (US), and AESKU GROUP GMBH & CO. KG (Germany).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.